Drug
Tabelecleucel
Tabelecleucel: highest development phase Phase 3, developed by Pierre Fabre. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Pierre Fabre
Trials
| Drug | Phase | Indication |
|---|---|---|
| tabelecleucel NCT03394365 | Phase 3 | Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD) |
| Tabelecleucel NCT04554914 | Phase 2 | Epstein-Barr Virus (EBV)-Associated Diseases |
Latest
No recent events.
Follow Tabelecleucel on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.